In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BrainCells gets $30mm in Series B, adds another $20mm

Executive Summary

New investor MedImmune Ventures took part in the $30mm Series B financing of BrainCells, which is redesigning small molecules to stimulate growth of new brain tissue. Existing shareholders Bay City Capital, Oxford Bioscience Partners, Technology Partners, Pappas Ventures, and NeuroVentures also participated. A MedImmune Ventures representative joined the company's board.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies